Liquid Biopsy in Cancer: What Can a Blood Test Really Tell Us?

What is a liquid biopsy?

Cancer may release cells, DNA fragments and other material into blood or another body fluid. Liquid-biopsy tests analyse some of that material. Many tests used for solid tumours focus on circulating tumour DNA, or ctDNA.

Everyone has small amounts of cell-free DNA in blood. Only a fraction may come from a tumour. The test tries to distinguish tumour-related information from this background, and the detectable amount varies substantially.

A ctDNA assay is not the same as an ordinary blood count or a tumour-marker test such as PSA or CA-125. These usually measure different things and answer different clinical questions.

When might a doctor recommend it?

It may help when a known cancer needs profiling but tissue is unavailable, inadequate or difficult to obtain safely. At progression it can sometimes identify changes relevant to resistance or a subsequent treatment. Blood and tissue testing may be used together.

Ask whether the result could change the next treatment, whether a specific alteration or broad panel is being examined and what happens if no useful finding is obtained.

Convenience does not remove the need for a suitable assay. A rapidly obtained result is valuable only if it answers the question reliably enough to guide a decision.

Does it replace tissue diagnosis?

Usually not for a newly diagnosed solid cancer. Tissue shows the cells under a microscope, helps establish the tumour’s origin and supports protein tests such as immunohistochemistry. These can distinguish cancers requiring very different treatment.

A liquid biopsy may identify an alteration without providing all that context. Finding a mutation associated with cancer is not always enough to establish the complete diagnosis or stage.

The choice is not which test is newer. It is which sample can answer the clinical question. Often tissue and blood are complementary rather than competing approaches.

Why can a negative result be misleading?

Some tumours release very little DNA into blood. Small disease volume, certain sites and effective treatment can reduce the signal. Tests also have detection limits and only examine the features included in their design.

“No alteration detected” can therefore mean no relevant change was present, insufficient tumour DNA reached the sample, or the change was outside the assay’s scope. It does not automatically mean no cancer or no useful target.

When blood profiling is negative or uninformative, tissue testing may still be needed. Ask how much confidence the team can place in the negative result and whether there was evidence of sufficient tumour-derived material.

Can a positive finding also need caution?

Not every detected alteration has a useful matching medicine. Some blood-DNA changes arise from non-cancerous blood-cell populations, called clonal haematopoiesis, rather than the solid tumour. An inherited variant may also need separate clarification.

Laboratory methods and clinical context help distinguish these possibilities. A highlighted gene on a report should not be converted straight into a prescription.

Ask which findings matter now, how strong the evidence is and whether another sample or specialist review is needed. A result can be biologically interesting without being clinically actionable.

Three uses that should not be confused

If the table extends beyond your screen, swipe or scroll sideways to read every column.

Different tests may use different technologies, have different approvals and apply to different patient groups. The label liquid biopsy should not obscure these distinctions.

What is molecular residual disease?

After treatment intended to eradicate cancer, a small amount may remain below the detection limit of scans. Some assays look for ctDNA as evidence of molecular or minimal residual disease, often called MRD.

Tumour-informed assays first examine the patient’s tumour and then look for selected changes in blood. Other assays use a strategy that does not first create a personalised panel from that tumour. Their validation and limitations differ.

A positive result can indicate a greater recurrence risk in particular cancers. But a predictive association alone does not establish which medicine to give, for how long or whether earlier intervention helps. That requires trials of the management strategy—not just laboratory detection.

Has ctDNA-guided treatment entered clinical practice?

Yes, in defined settings, and this is evolving. It would now be inaccurate to describe every action based on molecular residual disease as research only.

In May 2026, the US FDA approved atezolizumab for adults with muscle-invasive bladder cancer after cystectomy who have ctDNA-defined MRD detected by an FDA-authorised test, and approved a companion diagnostic for selection. The supporting IMvigor011 trial showed improvements in disease-free and overall survival in that selected population. This is a specific US-approved pathway, not a recommendation to treat a positive blood test in any cancer.

A separate example is the phase 3 SERENA-6 trial in a defined advanced hormone receptor-positive breast-cancer population. It tested a change in endocrine treatment after an ESR1 mutation emerged in blood, before scan progression, and demonstrated a progression-free survival benefit for that strategy. Published evidence, regulatory status and local guideline implementation remain separate questions.

These examples illustrate why the cancer, assay, timing and proposed action must match the evidence. Many other MRD or monitoring applications remain investigational or have a more limited role. Ask which category applies to the test being offered to you.

Can a blood test screen for every cancer?

No blood test reliably rules out every cancer. Multi-cancer detection tests search for biological signals associated with several cancers, but performance varies by tumour and stage. False positives can lead to additional procedures and anxiety; false negatives can create misplaced reassurance.

Do not use a negative result to ignore persistent symptoms or stop an established screening programme. A marketed blood test should not be assumed to replace recommended cervical, breast, bowel or lung screening.

A screening programme must ultimately be judged by whether using it improves meaningful outcomes with an acceptable balance of benefit and harm—not simply how many signals it detects.

What if the blood test and scan disagree?

They may be measuring different aspects of disease at different times and with different detection limits. A molecular result can be negative while a lesion remains visible, or a signal can appear before imaging identifies a definite site.

The team may review the assay, compare trends, repeat appropriate tests or investigate a specific area. Neither immediate treatment escalation nor automatic reassurance is appropriate without interpretation.

Ask for a defined plan: what is uncertain, what could resolve it and when it will be revisited. Repeating expensive tests without knowing what action the result would trigger can increase anxiety without improving care.

What should I clarify before a commercial test?

Ask the exact assay name, intended purpose, evidence for your cancer and whether it needs tissue as well as blood. Clarify the cost of the initial test and any recommended repeat testing.

Most importantly, establish what follows each result. Does a positive finding lead to a validated treatment, a trial discussion or further tests? Does a negative result need tissue profiling? Who will interpret it?

Do not assume that availability for purchase means proven usefulness for your situation. Equally, do not dismiss a test with a well-established role because other applications remain uncertain.

Frequently asked questions

Liquid biopsy is useful when the question, test and clinical action fit together. The blood sample is the simple part; interpretation is what gives it value.